In treatment combination approaches, Ataxia–Telangiectasia and Rad3-related protein (ATR) inhibitors are being studied in combination with ICI treatment in previously treated NSCLC patients [33]. This evidence concerns the gene ATR and non-small cell lung carcinoma.